The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers exhaustive insights into ...

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate ...

Orforglipron's launch and Medicare/Medicaid eligibility will expand Eli Lilly's addressable market and offset price erosion.

Dupixent growth offsets Eylea declines; pipeline/Libtayo impact post-2026; monitor ROIC & SBC. Click for a REGN update.

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

| DelveInsight The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based ...

(Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company Highlights The IMG-007 ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript March 12, 2026 Nektar Therapeutics beats earnings expectations. Reported EPS is $-1.77756, expectations were $-2.47411. Operator: ...